Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

  • There is currently no data for AGL

New Agreement

20 Jan 2005 07:01

Angle PLC20 January 2005 For Immediate Release 20 January 2005 ANGLE plc ANGLE signs Agreement with Ben Franklin Technology Partners to advance the growth of Technology Companies in Pennsylvania ANGLE plc, a leading international venture management and consulting companyfocusing on technology commercialisation today announced that it has signed aMemorandum of Understanding (MOU) with Ben Franklin Technology Partners ofSoutheastern Pennsylvania (BFTP/SEP), an internationally recognised economicdevelopment organisation, to advance the growth of technology-based companies inthe Greater Philadelphia region. Under the terms of the MOU, it is contemplated that ANGLE will commit no lessthan $5 million over five years for funding new technology spin-outs that meetits Progeny(R) requirements. This funding will be matched by BFTP/SEP - thusdoubling the leverage on ANGLE funds for creating ventures and similarlyleveraging BFTP/SEP's economic development funds. The Greater Philadelphia region is home to many of the world's most renownedacademic institutions including the University of Pennsylvania - one of theleading research universities in the United States. Collectively, the region'sacademic institutions attract more than $1 billion of research funding perannum, generating more than 200 patent applications per year. The region iswell recognised as a global leader in the bio-pharma and medical research arena. As part of the MOU, ANGLE will serve as BFTP/SEP's preferred commercialisationpartner for technologies from universities, colleges and related institutions inthe region, and become a corporate member of the Nanotechnology Institute, aninternationally recognised alliance of business, academia and government that isfacilitating the research and development and commercialisation of bio/nanoadvances. Commenting on the joint venture, Dr. Gary Evans, CEO of ANGLE's U.S. businessoperations said, "Our MOU and partnership with BFTP/SEP provides a uniqueopportunity both to extend our base of operation in the U.S. Mid-Atlantic regionand to complement an already robust technology commercialisation community. Inaddition to its formidable research capabilities, and its pre-eminentpharmaceutical industry, the region is highly regarded for developing newcutting edge research-to-commercialisation models around nanotechnology and bio/nanotechnology." "The ANGLE MOU is indicative of the synergy that occurs when distinct entitiesshare a common goal. It addresses critical management and capital needs at theearliest points in the commercialisation of new discoveries - just pasttranslational research to pre-seed, including pre-proof of concept,pre-prototype, pre-science/management team, pre-company formation. Liketechnology, this cross-Atlantic partnership has the potential to have asignificant global impact," said RoseAnn B. Rosenthal, president and CEO of BFTP/SEP. Andrew Newland, Chief Executive of ANGLE plc said, "This is a major developmentof our Ventures business in the U.S. It demonstrates the success of ourbusiness model and the leverage we generate between our Consulting and Venturesbusinesses. Our relationship with BFTP/SEP has developed from successfulconsulting work in Pennsylvania for Ben Franklin and others, including thedevelopment of the strategy for nanotechnology in the Commonwealth ofPennsylvania. We look forward to developing world-class ventures as a result ofthis expanded partnership." Notes to Editors: Founded in 1994, ANGLE is an international venture management and consultingcompany focusing on the commercialisation of technology and the development oftechnology-based industry. ANGLE creates, develops and advises technologybusinesses on its own behalf and for its clients. ANGLE plc floated on the Alternative Investment Market of the London StockExchange on 17 March 2004. About Ben Franklin Technology Partners of Southeastern Pennsylvania Since 1982, Ben Franklin Technology Partners of Southeastern Pennsylvania (BFTP/SEP) has helped grow the region through science, technology andentrepreneurship. BFTP/SEP provides entrepreneurs and established businesses thecapital, talent, and expertise they need to compete in the global marketplace.Like its namesake, Ben Franklin invests in, builds upon and delivers solutionsthat grow communities and create wealth by supporting today's technologicalideas and tomorrow's scientific discovery. For further information: ANGLE plc 01483 295830Andrew Newland, Chief ExecutiveDawson Buck, Deputy Chief Executive Buchanan Communications 020 7466 5000Richard Darby, Suzanne Brocks This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
27th Sep 20217:00 amRNSParsortix demonstrates ability to isolate CTCs
22nd Sep 20217:00 amRNSStudy shows use of Parsortix to assess PD-L1
20th Sep 20217:00 amRNSParsortix enables gene expression analysis in mPCa
7th Sep 20217:00 amRNSNotice of Interim Results and Webcast
24th Aug 20217:00 amRNSDirector/PDMR Shareholding
9th Aug 20217:00 amRNSStudy highlights superior performance of Parsortix
6th Aug 20211:17 pmRNSIssue of Equity
3rd Aug 20213:13 pmRNSIssue of Equity
28th Jul 20217:00 amRNSContract secured for bespoke assay development
9th Jul 20217:00 amRNSHarvesting CTCs from brain metastasis patients
7th Jul 20216:34 pmRNSDirector/PDMR Shareholding
2nd Jul 202110:45 amRNSIssue of Equity
30th Jun 20213:44 pmRNSResult of AGM
25th Jun 20217:00 amRNSResult of Accelerated Bookbuild
24th Jun 20216:28 pmRNSAccelerated bookbuild to raise up to £20m
18th Jun 202111:42 amRNSAnnual General Meeting update
18th Jun 20217:00 amRNSctDNA and CTCs have differences in EGFR mutations
4th Jun 20217:00 amRNSUpdate on submission for FDA clearance
1st Jun 20217:00 amRNSPotential to prevent breast cancer relapse
20th May 20217:00 amRNSParsortix demonstrates oesophageal cancer utility
19th May 20214:37 pmRNSExercise of options and total voting rights
11th May 20217:00 amRNSParsortix study uncovers targets in TNBC patients
30th Apr 202111:22 amRNSExercise of options and total voting rights
29th Apr 20217:00 amRNSPreliminary Results
26th Apr 20217:00 amRNSOvarian cancer study patient enrolment completed
19th Apr 20212:05 pmRNSSecond Price Monitoring Extn
19th Apr 20212:00 pmRNSPrice Monitoring Extension
19th Apr 202111:05 amRNSSecond Price Monitoring Extn
19th Apr 202111:00 amRNSPrice Monitoring Extension
16th Apr 20217:00 amRNSFirst large-scale pharma services contract secured
15th Apr 20214:10 pmRNSNotice of Preliminary Results and Webcast
12th Apr 20217:00 amRNSANGLE's Parsortix system showcased at AACR 2021
30th Mar 20217:00 amRNSGlobal launch of clinical services laboratories
4th Mar 20217:00 amRNSUpdate on submission for FDA clearance
18th Feb 20217:00 amRNSParsortix-harvested CTCs uncover novel biomarker
8th Feb 20217:00 amRNSParsortix: Dynamic assessment of patient response
29th Jan 20217:00 amRNSParsortix demonstrates high capture rate of CTCs
26th Jan 20211:00 pmRNSHolding(s) in Company
20th Jan 20217:00 amRNSResearch confirms high performance of Parsortix
12th Jan 20217:00 amRNSChange of Auditor
5th Jan 20217:00 amRNSIssue of Equity
9th Dec 20207:00 amRNSParsortix can capture single cancer cell in sample
20th Nov 20204:18 pmRNSHolding(s) in Company
18th Nov 20204:51 pmRNSHolding(s) in Company
13th Nov 202010:46 amRNSResult of General Meeting
3rd Nov 20202:54 pmRNSDirector/PDMR Shareholding
29th Oct 20207:00 amRNSInterim Results
27th Oct 20206:28 pmRNSResult of Placing & Notice of General Meeting
27th Oct 20207:00 amRNSAccelerated bookbuild to raise up to £20m
20th Oct 20207:00 amRNSSubmission accepted by FDA for substantive review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.